Table 1 Characteristics of adolescents and young adults with JIA
Variable | JIA | |||
|---|---|---|---|---|
total | 12-14 years | 15-17 years | 18-20 years | |
(n=628) | (n=182) | (n=234) | (n=212) | |
Sociodemographic data | ||||
Age, years, mean (SD) | 16.1 (2.5) | 13.0 (0.8) | 15.9 (0.8) | 19.0 (0.9) |
Female, no. (%) | 446 (71) | 130 (71) | 160 (68) | 156 (74) |
JIA category, no. (%) | ||||
Polyarthritis, adult type | 97 (15) | 21 (11) | 26 (11) | 50 (24) |
Polyarthritis, RF-negative | 195 (31) | 68 (37) | 71 (30) | 56 (26) |
Systemic JIA | 67 (11) | 16 (8.8) | 29 (12) | 22 (10) |
Oligoarthritis | 94 (15) | 37 (20) | 36 (15) | 21 (9.9) |
Psoriatic arthritis | 21 (3) | 5 (2.7) | 8 (3.4) | 8 (3.8) |
Enthesitis-related arthritis/juvenile spondyloarthritis | 57 (9) | 8 (4.4) | 29 (12) | 20 (9.4) |
Other JIA | 97 (15) | 27 (15) | 35 (15) | 35 (16) |
Antirheumatic therapy, no. (%) | ||||
Any b/cs/tsDMARD | 554 (88) | 165 (91) | 197 (84) | 192 (91) |
Any bDMARD | 371 (59) | 99 (54) | 129 (55) | 143 (67) |
Any csDMARD | 321 (51) | 111 (61) | 122 (52) | 88 (41) |
Any tsDMARD | 9 (1.4) | 3 (1.6) | 4 (1.7) | 2 (0.9) |
Any NSAID | 294 (47) | 79 (43) | 118 (50) | 97 (46) |
Systemic GCs | 190 (30) | 41 (22) | 79 (34) | 70 (33) |
GCs monotherapy | 74 (12) | 17 (9) | 37 (16) | 20 (9.4) |
Rheumatology care, no (%) | ||||
Total | 416 (66) | 119 (65) | 142 (61) | 155 (73) |
Pediatric | 297 (47) | 118 (65) | 133 (57) | 46 (22) |
Adult | 172 (27) | 8 (4.4) | 30 (13) | 134 (63) |